资讯

MyChesCo on MSN2 天
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial
New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...
MyChesCo on MSN2 天
FDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder Cancer
AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...